Researching: GLP-1

HHS' need for R&D speed; weird GLP-1 side effects

Magazine: Keep it cool

STAT+: Once described as obesity medicines for 'patients,' GLP-1s are increasingly lifestyle drugs for 'customers'

Roche's GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes

The Oral GLP-1 Tracker: Holiday takes toll on prescriptions

Are healthcare systems really ready for GLP-1s?

Artelo's ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice

Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis

Medicare’s $50 GLP-1 bridge model gives Lilly and Novo a demand signal

From his parents' basement to your medicine cabinet: Absci CEO endeavors to create biotech's Apple